AnaptysBio’s (ANAB) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of AnaptysBio (NASDAQ:ANAB) in a research note released on Thursday morning, Benzinga reports. The firm currently has a $55.00 price objective on the biotechnology company’s stock.

A number of other brokerages have also weighed in on ANAB. Wedbush reaffirmed an “outperform” rating and set a $42.00 price objective on shares of AnaptysBio in a report on Thursday, September 26th. Truist Financial upped their price objective on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. JPMorgan Chase & Co. upped their price objective on AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Guggenheim upped their price objective on AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, UBS Group upped their price objective on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, AnaptysBio presently has an average rating of “Moderate Buy” and an average price target of $55.73.

AnaptysBio Price Performance

AnaptysBio stock opened at $21.68 on Thursday. AnaptysBio has a 12 month low of $13.36 and a 12 month high of $41.31. The business has a 50 day simple moving average of $34.28 and a 200-day simple moving average of $29.88. The stock has a market capitalization of $594.77 million, a PE ratio of -3.41 and a beta of -0.29.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.82). AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The company had revenue of $10.97 million for the quarter, compared to analysts’ expectations of $25.85 million. As a group, equities research analysts anticipate that AnaptysBio will post -6.84 EPS for the current year.

Insider Activity

In other news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the sale, the insider now directly owns 15,398 shares in the company, valued at $595,440.66. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the sale, the insider now directly owns 15,398 shares in the company, valued at $595,440.66. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Dennis Mulroy sold 12,220 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the completion of the sale, the chief financial officer now owns 4,744 shares in the company, valued at $189,333.04. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,440 shares of company stock worth $892,936 over the last three months. 33.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On AnaptysBio

Large investors have recently added to or reduced their stakes in the business. Values First Advisors Inc. purchased a new position in AnaptysBio during the third quarter worth about $49,000. nVerses Capital LLC lifted its position in AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after buying an additional 1,400 shares during the period. Allspring Global Investments Holdings LLC purchased a new position in AnaptysBio during the first quarter worth about $38,000. Headlands Technologies LLC lifted its position in AnaptysBio by 444.8% during the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after buying an additional 2,900 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in AnaptysBio by 81.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock worth $195,000 after buying an additional 2,600 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.